AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19946413
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg/day
Trial: 19946413
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg/day and 300 mg/day
Trial: 19953376
Drug: Best possible
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best possible invasive therapy (endovascular, neurosurgical, and/or radiation therapy)
Trial: 19955196
Drug: High-dose 9-cis-beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 9-cis-beta-carotene (four capsules daily for 90 days)
Trial: 19962985
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin (264.3 +/- 25 mU/L)
Trial: 19963351
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support (parenteral nutrition)
Trial: 19965662
Drug: Fostamatinib disodium
RxNorm normalized name: fostamatinib disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib disodium 200 mg twice daily
Trial: 19995432
Drug: Mismatch concept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mismatch concept in acute stroke treatment using perfusion imaging (PI) with a fixed dosage of 5 ml 1 M Gadobutrol.
Trial: 19995432
Drug: Mismatch concept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mismatch concept in acute stroke treatment using perfusion imaging (PI).
Trial: 19995444
Drug: NIR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR treatment to left forehead (F3)
Trial: 19995444
Drug: NIR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR treatment to right forehead (F4)
Trial: 19995444
Drug: NIR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR treatment (on condition)
Trial: 19995444
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (light off)
Trial: 19996412
Drug: Deferasirox (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (mean dose 32.6 mg/kg per day) in the cardiac iron reduction arm
Trial: 20001658
Drug: Lipid-lowering drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drugs (LLD) for >3 months (stable medication >6 weeks)
Trial: 20001658
Drug: Good treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good treatment adherence
Trial: 20001856
Drug: Enfuvirtide-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide-containing therapy (including 2 reverse-transcriptase inhibitors and a ritonavir-boosted protease inhibitor) for at least 48 weeks
Trial: 20003269
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin (400 mg bid)
Trial: 20003832
Drug: Pegvisomant, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant, administered as daily subcutaneous injections adjusted according to IGF-I levels.
Trial: 20007560
Drug: Nonmyeloablative transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by G-CSF, with 300 cGy total-body irradiation plus alemtuzumab before transplantation and sirolimus afterward
Trial: 20007792
Drug: Sugammadex 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in renal patients
Trial: 20007792
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg(-1) in renal patients
Trial: 20007792
Drug: Sugammadex 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in healthy controls
Trial: 20007792
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg(-1) in healthy controls
Trial: 20007809
Drug: Intravenous PEG-asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PEG-asparaginase (2500 IU/m²) administered over 1 hour during remission induction
Trial: 20008298
Drug: CEP-701 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP-701 (80 mg orally twice daily)
Trial: 20014952
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg valacyclovir oral suspension (single dose)
Trial: 20014952
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg valacyclovir oral suspension (twice daily for 3-5 days)
Trial: 20014952
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg valacyclovir oral suspension (3 times daily for 5 days)
Trial: 20014952
Drug: Valacyclovir oral
RxNorm normalized name: valacyclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir oral suspension (various dosages)
Trial: 20015886
Drug: escalated imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) combined with intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7)
Trial: 20015886
Drug: escalated imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalated imatinib and intravenous cytarabine
Trial: 20027045
Drug: High concentrations
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentrations of Atopobium vaginae (10^6/mL or more)
Trial: 20027045
Drug: High concentrations
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentrations of Gardnerella vaginalis (10^7/mL or more)
Trial: 20027045
Drug: High concentrations
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentrations of A vaginae and G vaginalis together
Trial: 20027045
Drug: High vaginal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vaginal fluid concentrations of A vaginae and G vaginalis
Trial: 20028332
Drug: Tat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat vaccine administered 5 times, every four weeks, subcutaneously (SC) with alum adjuvant or intradermically (ID) without adjuvant at doses of 7.5 microg, 15 microg, or 30 microg.
Trial: 20028332
Drug: Tat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat vaccine (therapeutic immunization)
Trial: 20032009
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed to smokers (60%)
Trial: 20032009
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed to smokers
Trial: 20036194
Drug: Figitumumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab (20 mg/kg)
Trial: 20039404
Drug: Belimumab plus
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab plus standard of care therapy
Trial: 20041945
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (200-800 mg/day) infused over 10, 15, and 30 min for 2-5 days
Trial: 20042642
Drug: Glycerol solution
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol solution (0.57 g/mL) ingested at 3 mL/kg body weight (maximum, 250 mL)
Trial: 20045791
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg subcutaneous dose on day 9)
Trial: 20046132
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation therapy
Trial: 20048179
Drug: HAI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI of FUDR (0.2 mg/m²/d) and dexamethasone, alternating with systemic therapy of oxaliplatin (130 mg/m²) and capecitabine (1,000 mg/m² twice daily)
Trial: 20048179
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy of oxaliplatin (130 mg/m²) and capecitabine (1,000 mg/m² twice daily)
Trial: 20048179
Drug: HAI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI of FUDR and systemic therapy
Trial: 20048179
Drug: Protocol-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-directed therapy
Trial: 20051022
Drug: 1-year outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-year outpatient intervention based on exercise, behavior, and nutrition therapy
Trial: 20051130
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and SRT (COMB)
Trial: 20061136
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (cediranib and gefitinib)
Trial: 20061136
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of cediranib
Trial: 20061136
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of gefitinib
Trial: 20064072
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg vicriviroc
Trial: 20064072
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vicriviroc
Trial: 20064208
Drug: High Intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Intensity Interval Training (HIT) performed three times weekly by Group A participants.
Trial: 20064208
Drug: Moderate-vigorous physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-vigorous physical activity performed three times weekly by Group B participants.
Trial: 20065126
Drug: Pramipexole with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole with levodopa infusion
Trial: 20065758
Drug: Subcutaneous adiposity
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adiposity (141 patients)
Trial: 20067838
Drug: Plerixafor (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (single agent, subcutaneous)
Trial: 20071660
Drug: Infusions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions of donor-derived, ex vivo-expanded CD8(+) cytotoxic T lymphocyte (CTL) clones specific for tissue-restricted recipient mHAgs
Trial: 30118633
Drug: Challenge dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge dose of monovalent HBV vaccine
Trial: 20080236
Drug: Pitavastatin 4mg
RxNorm normalized name: PITAVASTATIN 4MG TAB
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4mg once daily
Trial: 20081096
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of electronic nose and FENO
Trial: 20082929
Drug: JUPITER-eligible individuals
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JUPITER-eligible individuals (hs-CRP > or = 2.0 mg/l, LDL-C <130 mg/dl)
Trial: 20087581
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with platinum/taxane-based regimen
Trial: 20088934
Drug: Dalteparin at
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin at a prophylactic dose
Trial: 20093349
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1000 mg orally, twice daily plus intravenous methylprednisolone (1 to 3 g) followed by oral prednisone (1 mg/kg per day)
Trial: 20095074
Drug: HAART initiated
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART initiated at CD4 cell counts 351-450 cells/ml
Trial: 20095074
Drug: CD4 cell
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell counts less than 200 cells/ml
Trial: 20095074
Drug: CD4 cell
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell counts 400-600 cells/ml
Trial: 20095074
Drug: CD4 cell
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell counts greater than 600 cells/ml
Trial: 20098694
Drug: Ixabepilone (BMS-247550)
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone (BMS-247550) at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle
Trial: 20101893
Drug: Baseline measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline measurements (before treatment)
Trial: 20106720
Drug: Neoadjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks) followed by chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily) and total mesorectal excision.
Trial: 20107214
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of live, oral rotavirus vaccine
Trial: 20107214
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of live, oral rotavirus vaccine
Trial: 20107229
Drug: Attainment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attainment of T-cell receptor rearrangement excision circle (TREC) levels of 2000 or more copies/mug DNA
Trial: 20110053
Drug: Nilotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib 200 mg (single oral dose)
Trial: 20111582
Drug: ADVAX (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX (0.2 mg)
Trial: 20111582
Drug: ADVAX (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX (1.0 mg)
Trial: 20111582
Drug: ADVAX (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAX (4.0 mg)
Trial: 20112079
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 600 mg administered 90 min prior to induction of anesthesia, then every eight hours for a total of four doses
Trial: 20112381
Drug: Tocilizumab 2
RxNorm normalized name: tocilizumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 2 mg/kg
Trial: 20119473
Drug: Point of
RxNorm normalized name: Precision Point of Care Test Strip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point of care (POC) urine drug testing
Trial: 20124511
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (50 mg/kg/d on days 3 and 4 after transplantation)
Trial: 20127732
Drug: High-dose silybin-phytosome
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose silybin-phytosome (13 g daily for 14-31 days, mean 20 days)
Trial: 20133465
Drug: Estrogen administration
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen administration after GnRH antagonist and graded doses of GnRH
Trial: 20133895
Drug: Dacetuzumab (SGN-40),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacetuzumab (SGN-40), 4 mg/kg and 12 mg/kg/week
Trial: 20133895
Drug: Dacetuzumab (SGN-40),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacetuzumab (SGN-40), 12 mg/kg/week
Trial: 20133895
Drug: Dacetuzumab (SGN-40)
RxNorm normalized name: dalotuzumab
DrugBank: Dacetuzumab (DB12589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacetuzumab (SGN-40) with steroid pre-medication
Trial: 20139774
Drug: 150 mg/m
RxNorm normalized name: urea 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m cyclophosphamide
Trial: 20139774
Drug: 250 mg/m
RxNorm normalized name: urea 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/m cyclophosphamide
Trial: 20139774
Drug: 350 mg/m
RxNorm normalized name: urea 350 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg/m cyclophosphamide
Trial: 20139774
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (150 and 250 mg/m)
Trial: 20142724
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg plus gefitinib 250 mg
Trial: 20147717
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (42.5 Gy in 16 fractions over 22 days)
Trial: 20147717
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy (50.0 Gy in 25 fractions over 35 days)
Trial: 20149262
Drug: Maintenance Sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Sorafenib (400 mg, p.o., twice a day for 12 months)
Trial: 20149262
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of 3DCRT/IMRT and TACE
Trial: 20149736
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously monthly (every 28 days), with loading doses on days 8 and 15 of month 1.
Trial: 20150297
Drug: Former intensive
RxNorm normalized name: Triple Wormer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former intensive insulin treatment
Trial: 20150297
Drug: Former conventional
RxNorm normalized name: Triple Wormer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former conventional insulin treatment
Trial: 20151726
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV esomeprazole (80 mg infusion over 30 min, then 8 mg/hour for 71.5 hours)
Trial: 20151726
Drug: No-IV esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-IV esomeprazole treatment
Trial: 20151726
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV esomeprazole
Trial: 20152220
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) with Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Trial: 20152220
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) with Angiotensin Receptor Blockers (ARBs)
Trial: 20152220
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) with ACEI or ARB
Trial: 20153880
Drug: Prophylactic Low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic Low Molecular Weight Heparin (LMWH)
Trial: 20153880
Drug: Adjusted-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose of LMWH through pregnancy and postpartum
Trial: 20156608
Drug: Postoperative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative management (medical therapy)
Trial: 20157136
Drug: Anticoagulants (90.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (90.5% of patients received anticoagulants)
Trial: 20157136
Drug: No anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulants (control group not explicitly mentioned)
Trial: 20160046
Drug: Famciclovir (individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir (individualized single doses based on body weight ranging from 25 to 175 mg)
Trial: 20163987
Drug: MTD gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTD gemcitabine (1000 mg/m² on days 1 and 8), metronomic capecitabine (500 mg/m² twice a day on days 1-14), and sorafenib (400 mg twice a day on days 1-21) for six cycles followed by sorafenib monotherapy if clinical benefit was maintained.
Trial: 20163987
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events related to the treatment regimen.
Trial: 20174766
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow (BM)-derived mononuclear cells administered to patients with limb ischaemia
Trial: 20174766
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell therapy for ischaemic peripheral disease